Booking Holdings Inc. (BKNG) vs Regeneron Pharmaceuticals, Inc. (REGN)
A side-by-side comparison of Booking Holdings Inc. and Regeneron Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 10, 2026. Differences are shown without an overall score or investment verdict.
Different business models: BKNG is classified in Consumer Cyclical; REGN is classified in Healthcare. Margin, capital intensity, and valuation differences should be interpreted in that sector context.
BKNG
Booking Holdings Inc.
$173.92Consumer CyclicalDelayed quote: Sep 11, 2026, 4:00 PM EDT
REGN
Regeneron Pharmaceuticals, Inc.
$781.49HealthcareDelayed quote: Sep 11, 2026, 4:00 PM EDT
Total return — BKNG vs REGN
growth of $100 · dividends reinvested · last 10yBKNG +218.8% (+12.3%/yr)REGN +108.5% (+7.6%/yr)BKNG compounded faster over this window
BKNG REGN
BKNG vs REGN: by the numbers
- •BKNG is the larger company ($134.77B vs $80.51B market cap).
- •REGN converts more revenue to profit (27.86% vs 25.53% net margin).
- •BKNG grew revenue faster over the past five years (31.52% vs 4.64% CAGR).
- •BKNG pays the higher dividend yield (0.92% vs 0.46%).
Metrics side by side
Valuation
| Metric | BKNG | REGN |
|---|---|---|
| P/E ratio | 19.29 | 19.33 |
| Forward P/E | 16.64 | 14.40 |
| P/S ratio | 4.77 | 5.18 |
| P/B ratio | N/A | 2.54 |
| EV / EBITDA | 13.30 | 17.79 |
| FCF yield | 7.08% | 4.37% |
Profitability
| Metric | BKNG | REGN |
|---|---|---|
| Gross margin | 100.00% | 84.86% |
| Operating margin | 34.49% | 25.56% |
| Net margin | 25.53% | 27.86% |
| ROE | N/A | 13.65% |
| ROIC | 71.23% | 9.19% |
Dividends
| Metric | BKNG | REGN |
|---|---|---|
| Dividend yield | 0.92% | 0.46% |
| Payout ratio | 17.83% | 9.15% |
Growth (annualized)
| Metric | BKNG | REGN |
|---|---|---|
| Revenue CAGR (5Y) | 31.52% | 4.64% |
| EPS CAGR (5Y) | 158.62% | 5.70% |
| FCF CAGR (5Y) | 56.15% | 15.77% |
| Total return CAGR (5Y) | 14.07% | 4.76% |
Frequently asked
- Which has the lower trailing P/E, BKNG or REGN?
- BKNG has the lower trailing P/E: BKNG trades at 19.29 and REGN at 19.33. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, BKNG or REGN?
- Over the past five years, BKNG grew revenue faster — BKNG at a 31.52% CAGR versus REGN at 4.64%.
- Does BKNG or REGN pay a bigger dividend?
- BKNG yields 0.92% and REGN yields 0.46% based on trailing dividends and the latest price.
- Is BKNG or REGN more profitable?
- REGN runs the higher net margin — BKNG at 25.53% versus REGN at 27.86%.
- How have BKNG and REGN total returns compared?
- Over the past 10 years, BKNG delivered 12.15% and REGN delivered 7.81% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Booking P/E ratioRegeneron Pharmaceuticals P/E ratioBooking dividend yieldRegeneron Pharmaceuticals dividend yieldBooking ROERegeneron Pharmaceuticals ROEBooking operating marginRegeneron Pharmaceuticals operating marginBooking revenue growthRegeneron Pharmaceuticals revenue growthBooking free cash flowRegeneron Pharmaceuticals free cash flow
Booking & Regeneron Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 10, 2026.